Clinical Toxicology Insights

Tox Pearls — one insight at a time.

Tox Pearls are one-page clinical insights from Dr. William Bundy Jr., PharmD — each covering a single toxicology concept that matters in practice. Free to download, share, and use. Written for clinicians and programs, published on LinkedIn.

5 Pearls Published
💡
One concept, one page

Each pearl covers a single clinical insight in depth — no filler, no padding. Designed to be read in under five minutes and applied the same day.

📥
Free to download and share

No paywall, no login required. Download for your program, share with colleagues, or print for patient education — no permission needed.

🔗
Evidence-based, practice-focused

Every pearl cites primary literature. Findings are translated into direct clinical language — what it means, and what to do with it.

Latest Pearl

Tox Pearls Series

Follow on LinkedIn →

Past Pearls

No. 04 Jun 2026 Semaglutide Reduces Opioid Overdose Risk. It Is Not an OUD Treatment.  ·  GLP-1 Medications  ·  OTP Practice Download
No. 03 May 2026 Six Months of MOUD Is Not Enough  ·  MOUD  ·  Opioid Use Disorder  ·  Treatment Duration Download
No. 02 May 2026 Naloxone Reverses the Apnea. It Does Not Reverse the Medetomidine.  ·  Fentanyl Adulterants  ·  Overdose Response Download
No. 01 May 2026 A Positive Immunoassay Is a Presumptive Result: Not a Diagnosis  ·  Urine Drug Testing  ·  Immunoassay vs. LC-MS/MS Download
About the Series

Clinical insights built for the moment between patients.

Tox Pearls exist because clinicians, drug court staff, and OTP programs often need fast, authoritative answers to complex toxicology questions. The literature is there; the time to read it usually is not.

Each pearl translates a specific, evidence-based concept into a one-page document you can read in the time it takes to walk to the next exam room. Shareable, citable, and free by design.

Follow Dr. Bundy on LinkedIn →
🧪
Drug testing interpretation

When to trust an immunoassay, when to order confirmation, and how to explain discrepant results to patients and courts.

💊
MOUD and addiction pharmacology

Practical guidance on medication selection, duration, adherence monitoring, and the science behind treatment decisions.

⚠️
Emerging substances and adulterants

Novel opioids, xylazine analogues, and other emerging threats — what they are, how they present, and what standard panels miss.

📌
Linked to deeper resources

When a pearl warrants full clinical reference depth, it connects to the corresponding Tox In Focus volume for the complete picture.

For educational purposes only. Tox Pearls are clinical education resources and do not constitute medical advice, legal guidance, or a substitute for professional judgment. Drug testing policies, clinical protocols, and relevant regulations vary by jurisdiction and setting. All clinical decisions should be made in consultation with qualified healthcare providers and in accordance with current guidelines, institutional policy, and applicable law. ToxiPharm LLC assumes no liability for decisions made based on these materials.
Stay Current
Get the full picture with ToxSignal.

Each issue of ToxSignal goes deeper — emerging drug threats, regulatory changes, and practice-relevant science, delivered free to your inbox. Tox Pearls and Tox In Focus volumes are always linked from inside each issue.

ToxSignal Newsletter

Get ToxSignal in Your Inbox

The clinical toxicology newsletter — drug trends, regulatory updates, and practice-relevant science, delivered free.

No spam. Unsubscribe anytime.